Pharma Reviews: Post GST domestic pharma companies to face headwinds in 1HFY18

Post GST domestic pharma companies to face headwinds in 1HFY18 ... too good for the Indian pharma companies in the first half of FY18 as well.
Read more: Post GST domestic pharma companies to face headwinds in 1HFY18